Abstract Introduction Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental disorder, with main manifestations related to communication, social interaction, and behavioral patterns. The slight dynamics of change in the child over time require that the onset of clinical manifestations presented by the child be more valued, with the aim of stabilizing the condition. Faced with a variety of methods for diagnosing ASD, the question arises as to which method should be used. This systematic review aims to recommend the best tools to perform screening and diagnosis. Methodology This systematic review followed the PRISMA guidelines. The databases MEDLINE, Embase, CENTRAL (Cochrane), and Lilacs were accessed, and gray and manual searches were performed. The search strategy was created with terms referring to autism and the diagnosis/broad filter. The studies were qualitatively evaluated and quantitatively. Statistical analysis was performed using Meta-diSc-2.0 software, the confidence interval was 95 %. Results The M-CHAT-R/F tool demonstrated a sensitivity of 78 % (95 % CI 0.57‒0.91) and specificity of 0.98 (95 % CI 0.88-1.00). The diagnostic tools demonstrated sensitivity and specificity respectively of: ADOS, sensitivity of 87 % (95 % CI 0.79‒0.92) and specificity 75 % (95 % CI 0.73‒0.78); ADI-R demonstrated test sensitivity of 77 % (95 % CI 0.56‒0.90) and specificity 68 % (95 % CI 0.52‒0.81), CARS test sensitivity was 89 % (95 % CI 0.78‒0.95) and specificity 79 % (95 % CI 0.65‒0.88). Conclusion It is mandatory to apply a screening test, the most recommended being the M-CHAT-R/F. For diagnosis CARS and ADOS are the most recommended tools. ASD (ASD disorder communication interaction patterns valued condition used guidelines MEDLINE Embase Cochrane, Cochrane , (Cochrane) accessed diagnosisbroad broad filter quantitatively MetadiSc2.0 MetadiSc20 MetadiSc Meta diSc 2.0 2 0 Meta-diSc-2. software 9 MCHATR/F MCHATRF M CHAT R/F R F 7 (9 0.57‒0.91 057091 57 91 098 98 0.9 0.881.00. 088100 0.88 1.00 . 88 1 00 0.88-1.00) 8 0.79‒0.92 079092 92 0.73‒0.78 073078 73 0.73‒0.78) ADIR ADI 0.56‒0.90 056090 56 90 6 0.52‒0.81, 052081 0.52‒0.81 52 81 0.52‒0.81) 0.78‒0.95 078095 0.65‒0.88. 065088 0.65‒0.88 65 0.65‒0.88) MCHATR/F. R/F. (Cochrane MetadiSc2 MetadiSc2. 20 2. Meta-diSc-2 MCHATR RF ( 0.57‒0.9 05709 5 09 0. 881 0.881.00 08810 088 0.8 100 1.0 0.88-1.00 0.79‒0.9 07909 0.73‒0.7 07307 0.56‒0.9 05609 05208 0.52‒0.8 0.78‒0.9 07809 06508 0.65‒0.8 Meta-diSc- 0.57‒0. 0570 0.881.0 0881 08 10 1. 0.88-1.0 0.79‒0. 0790 0.73‒0. 0730 0.56‒0. 0560 0520 0.52‒0. 0.78‒0. 0780 0650 0.65‒0. Meta-diSc 0.57‒0 057 0.881. 0.88-1. 0.79‒0 079 0.73‒0 073 0.56‒0 056 052 0.52‒0 0.78‒0 078 065 0.65‒0 0.57‒ 05 0.881 0.88-1 0.79‒ 07 0.73‒ 0.56‒ 0.52‒ 0.78‒ 06 0.65‒ 0.57 0.88- 0.79 0.73 0.56 0.52 0.78 0.65 0.5 0.7 0.6

RESUMO RACIONAL: O bypass gástrico de uma anastomose (BGU tem ganhado destaque na busca por melhores resultados na cirurgia bariátrica. No entanto, a eficácia e segurança do BGUA, em relação ao bypass gástrico em Y de Roux (BGYR) e à gastrectomia vertical (GV), permanecem imprecisas. OBJETIVOS: Comparar a eficácia e segurança do BGUA em relação ao BGYR e GV no tratamento da obesidade. MÉTODOS: Realizamos uma busca sistemática nas bases de dados do PubMed, EMBASE, Cochrane, Lilacs e Google Scholar por ensaios clínicos randomizados que comparassem o BGUA ao BGYR ou GV na abordagem cirúrgica da obesidade. Agrupamos resultados para índice de massa corporal, porcentagem da perda de peso em excesso, remissão do diabetes mellitus tipo 2, complicações e taxas de doença do refluxo gastroesofágico. As análises estatísticas foram realizadas empregando o software R, versão 4.2.3. RESULTADOS: Dados de 854 pacientes foram extraídos de 11 ensaios clínicos randomizados, dos quais 422 (49,4%) foram submetidos ao BGUA, com seguimento médio variando de seis meses a cinco anos. Na análise combinada, o BGUA esteve associado a uma porcentagem da perda de peso em excesso significativamente maior no acompanhamento de um ano e a um índice de massa corporal significativamente menor no acompanhamento de cinco anos em pacientes submetidos ao BGUA. Por outro lado, as taxas de remissão da diabetes mellitus tipo 2, de complicações e da doença do refluxo gastroesofágico não foram significativamente diferentes entre os grupos. A qualidade geral das evidências foi considerada muito baixa. CONCLUSÕES: Nossos resultados corroboram a eficácia comparável do BGUA em relação ao BGYR e GV no tratamento da obesidade, mantendo diferenças não significativas nas taxas de remissão da diabetes mellitus tipo 2, complicações e doença do refluxo gastroesofágico. RACIONAL BGU bariátrica entanto (BGYR GV, , (GV) imprecisas OBJETIVOS obesidade MÉTODOS PubMed EMBASE Cochrane 2 R 423 4 3 4.2.3 RESULTADOS 85 1 42 49,4% 494 49 (49,4% combinada lado grupos baixa CONCLUSÕES (GV 4.2. 8 49,4 (49,4 4.2 49, (49, 4. (49 (4 (

ABSTRACT BACKGROUND: One anastomosis gastric bypass (OAGB) has gained prominence in the search for better results in bariatric surgery. However, its efficacy and safety compared to Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) remain ill-defined. AIMS: To compare the efficacy and safety of OAGB relative to RYGB and SG in the treatment of obesity. METHODS: We systematically searched PubMed, EMBASE, Cochrane Library, Lilacs, and Google Scholar databases for randomized controlled trials comparing OAGB with RYGB or SG in the surgical approach to obesity. We pooled outcomes for body mass index, percentage of excess weight loss, type-2 diabetes mellitus remission, complications, and gastroesophageal reflux disease. Statistical analyses were performed with R software (version 4.2.3). RESULTS: Data on 854 patients were extracted from 11 randomized controlled trials, of which 422 (49.4%) were submitted to OAGB with mean follow-up ranging from six months to five years. The meta-analysis revealed a significantly higher percentage of excess weight loss at 1-year follow-up and a significantly lower body mass index at 5-year follow-up in OAGB patients. Conversely, rates of type-2 diabetes mellitus remission, complications, and gastroesophageal reflux disease were not significantly different between groups. The overall quality of evidence was considered very low. CONCLUSIONS: Our results corroborate the comparable efficacy of OAGB in relation to RYGB and SG in the treatment of obesity, maintaining no significant differences in type-2 diabetes mellitus remission, complications, and gastroesophageal reflux disease rates. BACKGROUND (OAGB surgery However RouxenY Roux en Y (RYGB (SG illdefined. illdefined ill defined. defined ill-defined AIMS obesity METHODS PubMed EMBASE Library Lilacs type2 type 2 type- remission complications version 4.2.3. 423 4.2.3 . 4 3 4.2.3) RESULTS 85 1 42 49.4% 494 49 (49.4% followup follow up years metaanalysis meta analysis 1year year 5year 5 Conversely groups low CONCLUSIONS 4.2. 8 49.4 (49.4 4.2 49. (49. 4. (49 (4 (

ABSTRACT Introduction: Chylothorax after thoracic surgery is a severe complication with high morbidity and mortality rate of 0.10 (95% confidence interval [CI] 0.06 – 0.02). There is no agreement on whether nonoperative treatment or early reoperation should be the initial intervention. This systematic review and meta-analysis aimed to evaluate the outcomes of the conservative approach to treat chyle leakage after cardiothoracic surgeries. Methods: A systematic review was conducted in PubMed®, Embase, Cochrane Library Central, and LILACS (Biblioteca Virtual em Saúde) databases; a manual search of references was also done. The inclusion criteria were patients who underwent cardiothoracic surgery, patients who received any nonoperative treatment (e.g., total parenteral nutrition, low-fat diet, medium chain triglycerides), and studies that evaluated chylothorax resolution, length of hospital stay, postoperative complications, infection, morbidity, and mortality. Central Message Nonoperative treatment for chylothorax after cardiothoracic procedures has significant hospital stay, morbidity, mortality, and reoperation rates. Results: Twenty-two articles were selected. Pulmonary complications, infections, and arrhythmia were the most common complications after surgical procedures. The incidence of chylothorax in cardiothoracic surgery was 1.8% (95% CI 1.7 – 2%). The mean time of maintenance of the chest tube was 16.08 days (95% CI 12.54 – 19.63), and the length of hospital stay was 23.74 days (95% CI 16.08 – 31.42) in patients with chylothorax receiving nonoperative treatment. Among patients that received conservative treatment, the morbidity event was 0.40 (95% CI 0.23 – 0.59), and reoperation rate was 0.37 (95% CI 0.27 – 0.49). Mortality rate was 0.10 (95% CI 0.06 – 0.02). Conclusion: Nonoperative treatment for chylothorax after cardiothoracic procedures has significant hospital stay, morbidity, mortality, and reoperation rates. Introduction 010 0 10 0.1 95% 95 (95 [CI 006 06 0.0 0.02. 002 0.02 . 02 0.02) intervention metaanalysis meta analysis surgeries Methods PubMed PubMed® Embase Biblioteca Saúde databases done e.g., eg e g (e.g. nutrition lowfat low fat diet triglycerides, triglycerides , triglycerides) resolution infection rates Results Twentytwo Twenty two selected infections 18 1 8 1.8 17 7 1. 2%. 2 2% 2%) 1608 16 08 16.0 1254 12 54 12.5 19.63, 1963 19.63 19 63 19.63) 2374 23 74 23.7 31.42 3142 31 42 040 40 0.4 023 0.2 0.59, 059 0.59 59 0.59) 037 37 0.3 027 27 0.49. 049 0.49 49 0.49) Conclusion 01 0. 9 (9 00 e.g. (e.g 160 16. 125 5 12. 196 19.6 6 237 23. 31.4 314 3 4 04 05 0.5 03 ( e.g 19. 31.